ALBUQUERQUE, N.M., Dec. 17 /PRNewswire-FirstCall/ -- The Board of Directors of Protalex, Inc. (OTC Bulletin Board: PRTX) announced today their selection of a new President and Chief Executive Officer, Mr. Steven H. Kane, of New Hope, PA. Kane comes to Protalex with over 23 years experience in the health care industry. Most recently he was Vice President of North American Sales & Field Operations for Aspect Medical. While at Aspect he guided the company through 12 quarters of successive growth resulting in a successful IPO in January 2000. Prior to Aspect, Kane was Eastern Area Vice President for Pyxis Corporation, where he was instrumental in positioning the company for its successful IPO in 1992. Pyxis later was acquired by Cardinal Health for $1 billion. Of the Protalex opportunity, Kane said; "Protalex is a company that is on the cutting edge of research and development in the treatment of a variety of autoimmune diseases, most notably Rheumatoid Arthritis. I feel fortunate to be joining a team that I consider to be of the highest caliber in the industry, and I am confident that Protalex will evolve as the leader in the emerging field of BioRegulation." Board member and outgoing CEO, John E. Doherty added, "We are extremely gratified that Steve has agreed to come on board at this critical time. His skills and experience will be invaluable as the Company makes the transition from development through regulatory approval to production and marketing of our first BioRegulator drug for Rheumatoid Arthritis." Statements in this press release that are not strictly historical are "forward looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include the Company's limited operating history, uncertainty regarding viability and market acceptance of the Company's products, and the Company's dependence on reimbursement by third parties. These factors and others are more fully described in the section entitled "Risks Related to the Company's Business" in the Company's Registration Statement on Form 10-SB (File No. 00028385) as filed with the Securities and Exchange Commission. MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X44874457
SOURCE Protalex, Inc.